| __timestamp | Opthea Limited | Travere Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 2652041 | 59644696 |
| Thursday, January 1, 2015 | 2361587 | 79541000 |
| Friday, January 1, 2016 | 4472869 | 98015000 |
| Sunday, January 1, 2017 | 5030957 | 103958000 |
| Monday, January 1, 2018 | 4988941 | 103654000 |
| Tuesday, January 1, 2019 | 5196412 | 128951000 |
| Wednesday, January 1, 2020 | 6652774 | 135799000 |
| Friday, January 1, 2021 | 18418247 | 149883000 |
| Saturday, January 1, 2022 | 24827066 | 220206000 |
| Sunday, January 1, 2023 | 41896408 | 265542000 |
| Monday, January 1, 2024 | 15488619 |
Unlocking the unknown
In the ever-evolving landscape of the pharmaceutical industry, understanding spending patterns is crucial. Over the past decade, Opthea Limited and Travere Therapeutics, Inc. have shown distinct trajectories in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Opthea's SG&A expenses surged by over 1,400%, peaking in 2023. In contrast, Travere's expenses grew steadily, reaching their zenith in 2023 with a 345% increase from 2014. This divergence highlights Opthea's aggressive expansion strategy, while Travere's consistent growth reflects a more stable approach. Notably, 2024 data for Travere is missing, leaving room for speculation on future trends. These insights offer a window into the strategic priorities of these companies, providing valuable context for investors and industry analysts alike.
SG&A Efficiency Analysis: Comparing AbbVie Inc. and Opthea Limited
Breaking Down SG&A Expenses: Gilead Sciences, Inc. vs Travere Therapeutics, Inc.
Regeneron Pharmaceuticals, Inc. or Opthea Limited: Who Manages SG&A Costs Better?
BeiGene, Ltd. or Opthea Limited: Who Manages SG&A Costs Better?
SG&A Efficiency Analysis: Comparing Summit Therapeutics Inc. and Travere Therapeutics, Inc.
SG&A Efficiency Analysis: Comparing Corcept Therapeutics Incorporated and Travere Therapeutics, Inc.
Cost Management Insights: SG&A Expenses for Ionis Pharmaceuticals, Inc. and Travere Therapeutics, Inc.
SG&A Efficiency Analysis: Comparing Opthea Limited and Protagonist Therapeutics, Inc.
Selling, General, and Administrative Costs: Verona Pharma plc vs Travere Therapeutics, Inc.
SG&A Efficiency Analysis: Comparing Mesoblast Limited and Travere Therapeutics, Inc.
Breaking Down SG&A Expenses: MannKind Corporation vs Travere Therapeutics, Inc.
SG&A Efficiency Analysis: Comparing Amphastar Pharmaceuticals, Inc. and Travere Therapeutics, Inc.